ANTIDIABETIC TREATMENT, OBESITY, AND CANCER RISK IN ALGERIAN PATIENTS WITH TYPE 2 DIABETES MELLITUS

被引:0
|
作者
Dennouni-Medjati, N. [1 ,2 ]
Dali-Sahi, M. [1 ,2 ]
Guermouche, B. [1 ,3 ]
Boudia, H. N. Merad [1 ,2 ]
Djelti, F. [1 ]
Harek, Y. [2 ]
Kachekouche, Y. [1 ]
机构
[1] Univ Tlemcen, Dept Biol, Tilimsen, Algeria
[2] Univ Tlemcen, Analyt Chem & Electrochem Lab, Tilimsen, Algeria
[3] Univ Tlemcen, Physiol Physiopathol & Biochem Nutr Lab, Tilimsen, Algeria
关键词
Type 2 diabetes mellitus; Cancer; Overweight; Insulin; Metformin; BREAST-CANCER; INSULIN; MALIGNANCIES; SURVIVAL;
D O I
10.32113/wcrj_20229_2394
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: Several studies have shown that antidiabetic drugs and obesity can modulate the risk of developing cancer. The objective of this study was to assess the impact of the use of antidiabetic drugs and obesity on the risk of developing cancers in type 2 diabetics. Materials and Methods: Data for 1220 patients were collected from the processing of files and a pre-established questionnaire. The anthropobiological parameters and the associated treatment type have been unspecified. Results: Women (OR=17.26; 95% CI=2.88-103.45, p < 0.01), overweight individuals (OR=4.81; 95% CI=1.63-14.14, p < 0.01) and hypertensive diabetic subjects (OR=3.82; 95% CI=1.39-10.49, p < 0.01) are more exposed to cancers. It is interesting to note that diabetic subjects treated with insulin have a reduced risk of developing cancer (OR= 0.22; 95% CI=0.07-0.67, p < 0.01). Diabetic subjects treated with metformin have a four and a half times higher risk of developing cancer (OR=4.61; 95% CI=1.48-14.37, p < 0.01). Conclusions: In type 2 diabetic subjects, cancer is significantly linked to overweight, to the presence of essential hypertension in individuals under hypotensive as well as in patients treated with metformin.
引用
收藏
页数:6
相关论文
共 50 条
  • [1] Obesity, Type 2 Diabetes, and Cancer Risk
    Scully, Tiffany
    Ettela, Abora
    LeRoith, Derek
    Gallagher, Emily Jane
    FRONTIERS IN ONCOLOGY, 2021, 10
  • [2] Treatment of type 2 diabetes mellitus and risk of pancreatic cancer
    Olakowska, Edyta
    Olakowski, Marek
    ENDOKRYNOLOGIA POLSKA, 2021, 72 (04) : 395 - 401
  • [3] Cancer risk in patients with type 2 diabetes mellitus and their relatives
    Liu, Xiangdong
    Hemminki, Kari
    Forsti, Asta
    Sundquist, Kristina
    Sundquist, Jan
    Ji, Jianguang
    INTERNATIONAL JOURNAL OF CANCER, 2015, 137 (04) : 903 - 910
  • [4] Rosiglitazone reduces breast cancer risk in Taiwanese female patients with type 2 diabetes mellitus
    Tseng, Chin-Hsiao
    ONCOTARGET, 2017, 8 (02) : 3042 - 3048
  • [5] Optimizing antidiabetic treatment options for patients with type 2 diabetes mellitus and cardiovascular comorbidities
    Malesker, Mark A.
    PHARMACOTHERAPY, 2008, 28 (02): : 193 - 206
  • [6] Diabetes: how to manage overweight and obesity in type 2 diabetes mellitus
    Wesling, Megan
    D'Souza, Jennifer J.
    DRUGS IN CONTEXT, 2022, 11
  • [7] Persistence of initial oral antidiabetic treatment in patients with type 2 diabetes mellitus
    Jermendy, Gyoergy
    Wittmann, Istvan
    Nagy, Laszlo
    Kiss, Zoltan
    Rokszin, Gyoergy
    Abonyi-Toth, Zsolt
    Katona, Lajos
    Paragh, Gyoergy
    Karadi, Istvan
    Merkely, Bela
    MEDICAL SCIENCE MONITOR, 2012, 18 (02): : CR72 - CR77
  • [8] Diabetes mellitus, medications for type 2 diabetes mellitus, and cancer risk
    La Vecchia, Carlo
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2011, 60 (10): : 1357 - 1358
  • [9] Retrospective database analysis of cancer risk in patients with type 2 diabetes mellitus in China
    He, Xiaoning
    Shi, Lizheng
    Wu, Jing
    CURRENT MEDICAL RESEARCH AND OPINION, 2018, 34 (06) : 1089 - 1098
  • [10] Gender-specific effects of oral hypoglycaemic agents on cancer risk in type 2 diabetes mellitus
    Sun, G. E. C.
    Wells, B. J.
    Yip, K.
    Zimmerman, R.
    Raghavan, D.
    Kattan, M. W.
    Kashyap, S. R.
    DIABETES OBESITY & METABOLISM, 2014, 16 (03) : 276 - 283